GlassScriptPhysician profile
Carla Walker Jorgensen
NPI 1841278512
$2,628.60
in general payments reported to CMS, 2019-2025
25 companies · $486 in 2025
The $486 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $438 · 2021: $67.79 · 2022: $204 · 2023: $970 · 2024: $463 · 2025: $486.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,919.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,919.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $381.06 | 2021-2025 | Trodelvy |
| E.R. Squibb & Sons, L.L.C. | $350.88 | 2022-2025 | Eliquis, Opdivo, Opdualag |
| Pfizer INC. | $269.46 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $215.93 | 2019-2025 | Andexxa |
| Novartis Pharmaceuticals Corporation | $192.64 | 2023-2025 | |
| Amgen INC. | $144.58 | 2022-2024 | Lumakras |
| Foundation Medicine, INC. | $140.69 | 2023 | |
| Mirati Therapeutics, INC. | $121.84 | 2023 | Krazati |
| Stemline Therapeutics INC. | $117.03 | 2023 | Orserdu |
| Pharmacyclics LLC, An Abbvie Company | $109.79 | 2019 | |
| Daiichi Sankyo INC. | $103.55 | 2023-2025 | Enhertu |
| Bayer Healthcare Pharmaceuticals INC. | $96.32 | 2023-2025 | |
| Karyopharm Therapeutics INC. | $70.55 | 2022 | |
| Lilly USA, LLC | $63.10 | 2023-2025 | Jaypirca, Verzenio, Retevmo |
| Boston Scientific Corporation | $55.87 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Taiho Oncology, INC. | $51.82 | 2025 | |
| Genentech USA, INC. | $29.86 | 2023 | Perjeta, Phesgo |
| Janssen Biotech, INC. | $23.12 | 2023 | Erleada, Imbruvica, Tecvayli |
| Kite Pharma, INC. | $22.49 | 2023 | |
| Pharmacosmos Therapeutics INC. | $19.98 | 2024 | Monoferric |
| Beigene USA, INC. | $16.83 | 2023 | Brukinsa |
| Celgene Corporation | $16.48 | 2025 | Opdivo |
| Array Biopharma INC | $14.73 | 2024 | Lorbrena, Braftovi, Mektovi |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carla Jorgensen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.